Oncolytic viruses (OVs) are at the cutting-edge of cancer treatment, offering exciting potential to transform patients’ health. However, their development requires specialist development and manufacturing infrastructure and expertise.
YOUR ONCOLYTIC VIRUS EXPERTS
Leading experts in oncolytic virus development and manufacture
The pioneering field of oncolytic viruses and cancer immunotherapies utilize a variety of viruses and vectors under current research and clinical trial – although limited commercial approvals exist to date. These products selectively infect and replicate in tumor tissues driving cell death and immune response. Ongoing trials include products utilizing many viruses as both monotherapy and in combination with additional modalities to drive enhanced efficacy. Our services are here to advance your OV innovation through clinical trial phases and beyond. We provide comprehensive services ranging from process development to GMP drug substance and drug product manufacturing, including aseptic processing capabilities. Our team of experts has a strong track record working with a variety of OV cell lines, including VERO, A549, HEK293 and Primary Chicken Embryonic Fibroblasts (CEFs). We have the capabilities to develop both cell-based (adherent and suspension) and egg-based oncolytic virus products.
Oncolytic Virus Experience
- Adenovirus (Ad)
- Herpes Simplex (HSV)
- Fowlpox (FPV)
- Newcastle Disease (NDV)
- Measles (MV)
- Vaccinia / Modified Vaccinia Ankara (MVA)
- Vesicular Stomatitis (VSV)
- Egg-based, Chick Embryo Fibroblasts (CEF), Continuous Cell Lines
Looking for something different?
Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.
Cell & Virus Banking
Virus Particle Analysis by MADLS Technology
Over the past two decades, we have seen continued advancement of virus characterization and quantification technologies come to market due to the progress made and demand from preclinical and clinical advancement of live viruses, vectored prophylactic vaccines, and gene therapy products to treat infectious diseases, cancer and various genetic disorders.